Eikon Therapeutics Inc EIKN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
-
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
-
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
-
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
-
Eikon Therapeutics to Participate in Investor Conferences in September 2026
-
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
-
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
-
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
Trading Information
- Previous Close Price
- $8.24
- Day Range
- $7.20–8.07
- 52-Week Range
- $6.45–17.40
- Bid/Ask
- $7.25 / $8.00
- Shares Outstanding
- 54.17M
- Market Cap
- $393.24M
- Volume/Avg
- 318,442 / 518,959
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 384
- Website
- https://www.eikontx.com
Valuation
|
Metric
|
EIKN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.84 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EIKN
|
|---|---|
Quick Ratio | 9.61 |
Current Ratio | 9.89 |
Interest Coverage | — |
Quick Ratio
EIKN
Profitability
|
Metric
|
EIKN
|
|---|---|
Return on Assets (Normalized) | −42.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −382.03% |
Return on Assets
EIKN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VJd%Sr# | LOCK|vp@d@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xnp<wd | LOCK|@>>$M | $83B | |||
| Moderna Inc
MRNA
| LOCK|!&$Vc? | LOCK|tm< | $80B | |||
| argenx SE ADR
ARGX
| LOCK|F##tdz | LOCK|cZ% | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?zB!R% | LOCK|^v | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$?>s^nM | LOCK|@Dm%^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|HLmPC!$ | LOCK|&#$@X | $28B | |||
| Incyte Corp
INCY
| LOCK|LZjrZH | LOCK|JW! | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>C@gM&j | LOCK|tD | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j^RCpy | LOCK|vHC | $14B |
United States